These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22112682)

  • 1. A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers.
    Konoshita T; Makino Y; Kimura T; Fujii M; Morikawa N; Wakahara S; Arakawa K; Inoki I; Nakamura H; Miyamori I;
    Int J Cardiol; 2013 Jun; 166(2):448-52. PubMed ID: 22112682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
    Konoshita T; Kaeriyama S; Urabe M; Nakaya T; Yamada M; Ichikawa M; Yamamoto K; Sato S; Imagawa M; Fujii M; Makino Y; Zenimaru Y; Wakahara S; Suzuki J; Ishizuka T; Nakamura H;
    Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Fukumoto S; Ishimura E; Motoyama K; Morioka T; Kimoto E; Wakikawa K; Shoji S; Koyama H; Shoji T; Emoto M; Nishizawa Y; Inaba M;
    Diabetes Res Clin Pract; 2012 Jul; 97(1):91-8. PubMed ID: 22336632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Matsuoka H; Ando K; Ueshima K; Babazono T; Kario K; Tanaka S; Nakao K; Fujita T;
    Clin Exp Hypertens; 2011; 33(7):455-62. PubMed ID: 21649534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
    Morimoto S; Yano Y; Maki K; Iwasaka T
    J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
    Abe M; Maruyama N; Suzuki H; Inoshita A; Yoshida Y; Okada K; Soma M
    Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.
    Yamada H; Suga N; Maeda K; Kimura Y; Miura N; Futenma A; Imai H
    Arzneimittelforschung; 2010; 60(2):64-70. PubMed ID: 20329653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension.
    Ogura C; Ono K; Miyamoto S; Ikai A; Mitani S; Sugimoto N; Tanaka S; Fujita M
    Blood Press; 2012 Dec; 21(6):367-71. PubMed ID: 22747420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial.
    Hwang YC; Yoon KH; Cha BS; Lee KW; Jang HC; Min KW; Chung CH; Lee MK
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28840637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker.
    Konoshita T; Makino Y; Kimura T; Fujii M; Wakahara S; Arakawa K; Inoki I; Nakamura H; Miyamori I;
    J Hypertens; 2010 Oct; 28(10):2156-60. PubMed ID: 20625317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Ando K; Ueshima K; Tanaka S; Kosugi S; Sato T; Matsuoka H; Nakao K; Fujita T
    Int J Med Sci; 2013; 10(9):1209-16. PubMed ID: 23935398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
    Miyagawa K; Dohi Y; Nakazawa A; Sugiura T; Yamashita S; Sato K; Kimura G
    Clin Exp Hypertens; 2010 Jan; 32(1):1-7. PubMed ID: 20144066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate.
    Nakagawa N; Fujino T; Kabara M; Matsuki M; Chinda J; Kikuchi K; Hasebe N;
    Hypertens Res; 2011 Oct; 34(10):1121-6. PubMed ID: 21796123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
    Miwa Y; Tsuchihashi T; Ohta Y; Tominaga M; Kawano Y; Sasaguri T; Ueno M; Matsuoka H
    Clin Exp Hypertens; 2010; 32(6):400-5. PubMed ID: 20828221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: internet-mediated open-label crossover trial of calcium channel blockers for hypertension (i-TECHO trial).
    Ryuzaki M; Nakamoto H; Nishida E; Sone M; Nakajima S; Yoshimoto M; Suzuki Y; Itagaki K
    J Hypertens; 2007 Nov; 25(11):2352-8. PubMed ID: 17921832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.
    Saito F; Fujita H; Takahashi A; Ichiyama I; Harasawa S; Oiwa K; Takahashi N; Otsuka Y; Uchiyama T; Kanmatsuse K; Kushiro T
    Hypertens Res; 2007 Jan; 30(1):39-47. PubMed ID: 17460370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
    Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H
    Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients: a novel effect to be explained with hyperfiltration?
    Ay SA; Cakar M; Karaman M; Balta S; Demirkol S; Unlu M; Kurt O; Altun B; Akhan M; Arslan E; Koc B; Bulucu F
    Ren Fail; 2013; 35(3):357-60. PubMed ID: 23297711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.